The Wnt pathway protein Dvl1 targets somatostatin receptor 2 for lysosome-dependent degradation

• Published in: The Journal of biological chemistry 2023-05, Vol.299 (5), p.104645-104645, Article 104645
• Main Authors: Carr, Heather S., Zuo, Yan, Frost, Jeffrey A.
• Format: Article
• Language: English
• Subjects: cell signaling; Dishevelled Proteins - genetics; Dishevelled Proteins - metabolism; Dvl1; G protein-coupled receptor (GPCR); Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HEK293 Cells; Humans; lysosome; Lysosomes - metabolism; Neuroendocrine Tumors - physiopathology; Protein Binding; Protein Transport; Receptors, Somatostatin - genetics; Receptors, Somatostatin - metabolism; Somatostatin; Sstr2; ubiquitin; Wnt
• ISSN: 0021-9258; 1083-351X
• DOI: 10.1016/j.jbc.2023.104645

The Somatostatin receptor 2 (Sstr2) is a heterotrimeric G protein-coupled receptor that is highly expressed in neuroendocrine tumors and is a common pharmacological target for intervention. Unfortunately, not all neuroendocrine tumors express Sstr2, and Sstr2 expression can be downregulated with prolonged agonist use. Sstr2 is rapidly internalized following agonist stimulation and, in the short term, is quantitatively recycled back to the plasma membrane. However, mechanisms controlling steady state expression of Sstr2 in the absence of agonist are less well described. Here, we show that Sstr2 interacts with the Wnt pathway protein Dvl1 in a ligand-independent manner to target Sstr2 for lysosomal degradation. Interaction of Sstr2 with Dvl1 does not affect receptor internalization, recycling, or signaling to adenylyl cyclase but does suppress agonist-stimulated ERK1/2 activation. Importantly, Dvl1-dependent degradation of Sstr2 can be stimulated by overexpression of Wnts and treatment of cells with Wnt pathway inhibitors can boost Sstr2 expression in neuroendocrine tumor cells. Taken together, this study identifies for the first time a mechanism that targets Sstr2 for lysosomal degradation that is independent of Sstr2 agonist and can be potentiated by Wnt ligand. Intervention in this signaling mechanism has the potential to elevate Sstr2 expression in neuroendocrine tumors and enhance Sstr2-directed therapies.